||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 535 active entries
Technion city, Gutwirth Park
Haifa 32000, ISRAEL
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Surgical Bio-Polymeric Materials (SBPM) Ltd. was established in 1992 as a private company, the shares of which are divided between two scientists who developed the know-how Dimotech Ltd., a subsidiary company of the Technion Research and Development Foundation Ltd., and a third foreign partner. SBPM is developing new polymeric materials for biocompatible and biodegradable bone adhesives. They seek to promote the natural process of bone reconstitution through the provision of a porous structure into which the bone tissue can grow, and which gradually disappears until natural bone has taken over. The company consists of two main groups (9 scientists, 6 of whom have Ph.D. degree), pursuing in-vivo and in-vitro research. The in-vivo experiments are performed at the animal farm in the Technion’s Faculty of Medicine, Rambam Medical Center.
A polymeric bone adhesive, having a short setting time, that forms a porous material, into which natural bone substance can grow and ultimately restore the bone’s natural shape and consistency. It becomes tacky on application and permits exact bone adjustments to be made prior to its setting. It then rapidly polymerizes, assuming the stiff, porous form, allowing the natural growth of the bone to fill the interstices. The adhesive gradually disintegrates and biodegrades, leaving the bone to complete its healing. Thus, the adhesive is considered as a temporary implant.
The adhesive is especially advantageous for complicated fractures or restorations, which currently require mechanical means of joining and support that often necessitate their later removal is necessary. Attempts to use adhesives for holding bone fragments together have so far failed for lack of Biocompatibility and toxicity. The materials under present development are not rejected by either bone or surrounding tissue.
Current Project Status
In-vitro tests, at conditions simulating those within the human body, have shown that the strength of the joints is maintained for an extended period of time, followed by strength deterioration and adhesive degradation. The polymerization and degradation processes have undergone investigation. In-vivo testing has, till now, indicated that the presence of the adhesive in animals causes no adverse reactions and no signs of rejection were found. The bone fragments had not moved from the location where they had been glued and in growth of new connective tissue in the adhesive was found, proving the presence of a healing process. Further in-vivo tests, including histological investigations are continuing.
Registered in Israel and the USA.
Applications were filed in Canada, Japan, Switzerland, France, Great Britain, Italy, The Netherlands and Germany.
Dimotech Ltd. is a company wholly owned by the Technion Research and Development Foundation Ltd. TDRF) Its main purpose is to find the research projects of the Technion researchers which can be commercialized in a way which will bring benefits to the Technion and the academic community in Israel.
Dimotech Ltd. assists in the establishment of enterprises based on high technology and provides entrepreneurs, all of them staff members of the Technion, with facilities for the development of their inventions and ideas. All the employees of Dimotech Ltd. are experienced specialists in technical and economical fields they are involved in.
The Technion Research and Development Foundation Ltd., was established 40 years ago as a wholly-owned subsidiary company of the Technion. Its aim was to carry out sponsored research and experimental scientific programs, to provide testing, technical services and other investigative procedures, necessary for development and commercialization of the potential offered by the Technion’s inventions and patents. The inventions and know-how resulting from research programs are commercialized by means of licensing arrangements with local and foreign industry, or through establishing subsidiary start-up activities in collaboration with strategic partners. The experience gained so far shows that the combination of outstanding technologies and a competent management with appropriate strategic partners can result in the development of successful businesses and creation of new employment opportunities.
Last update of this entry: before October 1999.